Toll-like receptor 3 increases antigen-presenting cell responses to a pro-apoptotic stimulus, yet does not contribute to systemic lupus erythematosus genetic susceptibility.
Aurélie De GroofJean‐Pierre PignonLaura Vidal-BraloDonatienne TytecaChristine GalantLiliane MarotPierre G. CoulieBenoı̂t J. Van den EyndeLorena Rodríguez-MartínezMaría José SantosAna SuárezPatrícia CarreiraMaurizio MarchiniAntonio GonzálezFrédéric HoussiauBernard Lauwerys
3
Citation
0
Reference
10
Related Paper
Citation Trend
Abstract:
TLR3 mediates skin solar injury by binding nuclear material released from apoptotic keratinocytes, resulting in the production of pro-inflammatory cytokines. Because the TLR3 gene is located in 4q35, a known systemic lupus erythematosus (SLE) susceptibility locus, we wondered whether TLR3 single nucleotide polymorphisms (SNPs) were associated with inflammatory mechanisms relevant to the development of SLE, and disease susceptibility.Functional assays were carried out in TLR3-transfected HEK293 cells and in monocyte-derived dendritic cells (moDCs). TLR3 and IFNβ immunofluorescence studies were performed in skin samples from 7 SLE patients and 3 controls. We performed a SNP association study in a discovery cohort of 153 patients and 105 controls, followed by a confirmation study in an independent cohort of 1,380 patients and 2,104 controls.TLR3 and IFNβ are overexpressed in SLE skin lesions. TLR3 overexpression in HEK293 cells amplifies their sensitivity to a pro-apoptotic stimulus. Taking advantage of a naturally occurring polymorphic TLR3 variant (rs3775291) that weakly versus strongly responds to poly I:C stimulation, we found that TLR3 is associated with amplified apoptotic responses, production of the Ro/SSA autoantigen and increased maturation of myeloid-derived dendritic cells (moDC) after exposure to UV irradiation. However, TLR3 SNPs are not associated with susceptibility to SLE in a large population of patients and controls.TLR3 is overexpressed in SLE skin lesions and amplifies apoptotic and inflammatory responses to UV-irradiation in antigen-presenting cells in vitro. However, TLR3 SNPs do not impact susceptibility to the development of the disease.Keywords:
TLR7
TLR3
Cite
Lymphoblast
Lymphoblastic lymphoma
Precursor cell
Cite
Citations (16)
MUC1
Cite
Citations (0)
Clonogenic assay
Cord blood
Cite
Citations (11)
Ovarian cancer is the fifth leading cause of cancer deaths among women and the most common type of gynecologic malignancy. Despite advances in surgery and chemotherapy, the survival rate of patients with epithelial ovarian cancer is still low. For a whole decade, that situation has not improved. Most ovarian cancer patients relapse and become drug-resistant. Increasing evidence has suggested that tumor growth capability is dependent upon cancer stem cells (CSCs) that represent a small subset of cells within a variety of human tumors. In immunocompromised mice, CSCs were assayed by their ability to initiate tumor growth. Although still being explored, the ovarian CSCs, which have been found in several ovarian cancer cell lines, are within a mixed population of cells derived from the ascites of a patient with advanced ovarian cancer. Hope may lie in killing of the ovarian CSCs. They are also likely to be the therapeutic target in the treatment of epithelial ovarian cancer. Thus, a thorough understanding of CSCs' biology, particularly of how they differ from ordinary cancer cells and normal stem cells, might lead to a more effective ovarian cancer therapeutic strategy involving the selective targeting and elimination of ovarian CSCs.
Cite
Citations (18)
Multiple myeloma (MM) is a common B-cell malignancy characterized by clonal expansion of transformed plasma cells in the bone marrow. 1 Natural history of MM is characterized by disease progression, and the development of anemia, lytic bone disease, and infections. However, although clonal expansion of transformed plasma cells is an essential prerequisite for the development of MM, the most common clinical outcome of such expansions in vivo in humans is not MM, but the development of monoclonal gammopathy of undetermined significance (MGUS). MGUS has been estimated to occur in up to 1–3% of the elderly population, and is commonly viewed as a preneoplastic state. However, most patients with MGUS will generally remain stable throughout their life, and only a small proportion (estimated at about 1% per year) will develop MM. 2 Another clinically distinct subset is patients with asymptomatic MM, who also have a relatively indolent course, but much higher risk for transformation to symptomatic MM. 3 Recent application of interphase cytogenetics and genomic technologies has yielded the surprising finding that many of the cytogenetic and genomic changes in tumor cells initially identified in MM can now also be detected in the tumor cells in MGUS. 4 , 5 In many instances, genetic lesions such as deletion of chromosome 13 that seem to impart an adverse outcome in MM do not do so in MGUS. These findings therefore suggest the possibility that clinical outcome in MM depends not only on the properties of the tumor cells themselves but also on changes in the host tumor microenvironment and their interactions with the tumor cells. An important component of this microenvironment is the cells of the immune system. 6 Therefore, improved understanding of the immune microenvironment in MM might provide newer approaches for therapy and prevention of this disease. Below, I will first briefly discuss some of the general principles underlying the mechanisms of immune control and escape of tumors, and then describe the current studies about the status of immune cells in MM and MGUS. Understanding the status of the host immune response is an essential first step for optimal development of therapeutic approaches targeting the immune system in MM. Chapter 11
Cite
Citations (0)
Type 1 diabetes is characterized by the selective destruction of pancreatic β-cells caused by an autoimmune attack.Restoration of damaged β-cells by transplantation from exogenous sources or by endocrine pancreas regeneration would be ideal therapeutic options.Stem cells of both embryonic and adult origin offer some interesting alternatives,taking into account the latest advances indicating that these cells could be the potential building blocks from which insulin secreting cells could be obtained in vitro under appropriate culture conditions.Although it has been reported that insulin-producing cells derived from stem cells have been shown to reverse experimentally induced diabetes in animal models,several concerns need to be solved before finding a definite medical application.These refer mainly to the obtainment of a cell population as similar as possible to pancreatic β-cells,and to the problems related with the immune compatibility and tumor formation.This review will describe the different approaches that have been used to obtain insulin-producing cells from embryonic and adult stem cells,the effect of cell transplantation for treating type 1 diabetes mellitus and analyze the main problems of therapy with these stem cells and the possible solving methods.
Cell therapy
Regenerative Medicine
Cite
Citations (0)
Active immunotherapy
Cite
Citations (9)
Minimal Residual Disease
Cite
Citations (4)